NewLink Genetics Corporation (NASDAQ:NLNK) was upgraded by analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating in a research report issued on Friday. The brokerage currently has a $22.00 target price on the biotechnology company’s stock, up from their previous target price of $8.00. Robert W. Baird’s target price would suggest a potential upside of 61.76% from the company’s current price.

A number of other equities research analysts have also recently commented on the stock. Jefferies Group LLC upgraded shares of NewLink Genetics Corporation from a “hold” rating to a “buy” rating in a report on Friday. ValuEngine upgraded shares of NewLink Genetics Corporation from a “strong sell” rating to a “sell” rating in a report on Thursday. Cantor Fitzgerald set a $26.00 price target on shares of NewLink Genetics Corporation and gave the company a “buy” rating in a report on Friday, July 28th. Finally, Zacks Investment Research upgraded shares of NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a report on Saturday, July 29th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. NewLink Genetics Corporation has an average rating of “Buy” and an average price target of $20.50.

NewLink Genetics Corporation (NASDAQ:NLNK) traded up 33.01% during trading on Friday, reaching $18.09. The company’s stock had a trading volume of 29,098,926 shares. NewLink Genetics Corporation has a one year low of $5.90 and a one year high of $25.17. The firm’s market cap is $532.23 million. The company has a 50-day moving average of $7.21 and a 200 day moving average of $12.81.

NewLink Genetics Corporation (NASDAQ:NLNK) last posted its quarterly earnings results on Friday, July 28th. The biotechnology company reported ($0.57) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.21. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. The firm had revenue of $10.37 million for the quarter, compared to analysts’ expectations of $2.65 million. Analysts expect that NewLink Genetics Corporation will post ($2.82) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2017/09/08/newlink-genetics-corporation-nlnk-stock-rating-upgraded-by-robert-w-baird.html.

A number of hedge funds have recently modified their holdings of the stock. Orbimed Advisors LLC boosted its holdings in NewLink Genetics Corporation by 2.8% in the fourth quarter. Orbimed Advisors LLC now owns 1,991,700 shares of the biotechnology company’s stock worth $20,475,000 after purchasing an additional 53,400 shares during the last quarter. BlackRock Fund Advisors boosted its holdings in NewLink Genetics Corporation by 8.5% in the first quarter. BlackRock Fund Advisors now owns 1,185,912 shares of the biotechnology company’s stock worth $21,584,000 after purchasing an additional 92,818 shares during the last quarter. State Street Corp boosted its holdings in NewLink Genetics Corporation by 21.4% in the first quarter. State Street Corp now owns 1,147,096 shares of the biotechnology company’s stock worth $20,876,000 after purchasing an additional 202,499 shares during the last quarter. Vanguard Group Inc. boosted its holdings in NewLink Genetics Corporation by 5.6% in the first quarter. Vanguard Group Inc. now owns 959,883 shares of the biotechnology company’s stock worth $23,134,000 after purchasing an additional 51,013 shares during the last quarter. Finally, FMR LLC boosted its holdings in NewLink Genetics Corporation by 119.3% in the fourth quarter. FMR LLC now owns 904,856 shares of the biotechnology company’s stock worth $9,302,000 after purchasing an additional 492,330 shares during the last quarter. Institutional investors own 54.78% of the company’s stock.

NewLink Genetics Corporation Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.